Department of Fundamental Chemistry, Institute of Chemistry, University of São Paulo, São Paulo, SP, Brazil.
Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, USA.
Biometals. 2021 Apr;34(2):259-275. doi: 10.1007/s10534-020-00277-7. Epub 2021 Jan 3.
Alzheimer's Disease (AD) is a complex neurodegenerative disorder associated in some instances with dyshomeostasis of redox-active metal ions, such as copper and iron. In this work, we investigated whether the conjugation of various aromatic amines would improve the pharmacological efficacy of the iron chelator desferrioxamine (DFO). Conjugates of DFO with aniline (DFOANI), benzosulfanylamide (DFOBAN), 2-naphthalenamine (DFONAF) and 6-quinolinamine (DFOQUN) were obtained and their properties examined. DFOQUN had good chelating activity, promoted a significant increase in the inhibition of β-amyloid peptide aggregation when compared to DFO, and also inhibited acetylcholinesterase (AChE) activity both in vitro and in vivo (Caenorhabditis elegans). These data indicate that the covalent conjugation of a strong iron chelator to an AChE inhibitor offers a powerful approach for the amelioration of iron-induced neurotoxicity symptoms.
阿尔茨海默病(AD)是一种复杂的神经退行性疾病,在某些情况下与氧化还原活性金属离子(如铜和铁)的动态平衡失调有关。在这项工作中,我们研究了将各种芳族胺缀合是否会提高铁螯合剂去铁胺(DFO)的药理功效。DFO 与苯胺(DFOANI)、苯并硫酰胺(DFOBAN)、2-萘胺(DFONAF)和 6-喹啉胺(DFOQUN)的缀合物已被获得,并对其性质进行了研究。DFOQUN 具有良好的螯合活性,与 DFO 相比,可显著促进β-淀粉样肽聚集的抑制作用,并且还可抑制乙酰胆碱酯酶(AChE)的体外和体内(秀丽隐杆线虫)活性。这些数据表明,将强铁螯合剂与 AChE 抑制剂共价缀合为改善铁诱导的神经毒性症状提供了一种有力的方法。